Pfizer Q1 preview: Where next for Pfizer stock?

When will Pfizer release Q1 2022 earnings?

Pfizer is scheduled to publish first quarter earnings for 2022 before US markets open on Tuesday May 3.

Pfizer Q1 earnings preview

Pfizer celebrated a record year in 2021 as its Covid-19 vaccine that was developed in partnership with European outfit BioNTech transformed its finances and was the main driver behind the company’s revenue almost doubling last year. In fact, having had no Covid-19 drugs within its portfolio in 2019, its vaccine and its newer Paxlovid treatment accounted for a whopping $36.9 billion of Pfizer’s $81.3 billion of revenue in 2021.

Wall Street forecasts Pfizer’s revenue will jump over 67% year-on-year to $24.35 billion in the first quarter and that adjusted EPS will follow 66% higher to $1.55.

This will once again be boosted by sales of its Covid-19 drugs as it comes up against fairly weak comparatives from early last year, when sales of its jab were only just starting to take off. Analysts believe Pfizer sold $10.6 billion worth of its vaccine in the first quarter and $2.4 billion of Paxlovid, which is only just starting to gain traction.

Paxlovid sales have only recently started, so will only add to the topline in 2022 and provide the biggest catalyst this year. Analysts at Bloomberg Intelligence suggests every $10 billion of Paxlovid sales will add around $1 to EPS and boost cash generation by $7 billion. With this in mind, Pfizer has said it expects to sell $32 billion worth of its Covid-19 vaccine in 2022 and deliver $22 billion of Paxlovid sales. This means Pfizer’s Covid-19 drugs will account for over half of its total revenue this year.

The outlook for 2022 will go a long way in deciding how markets react to the results this week as investors gauge how confident Pfizer is feeling about the rest of the year. Importantly, this will be the easiest quarter in terms of comparatives for both revenue and earnings, which will both become harder to top as the year goes on and likely to lead to a slowdown in growth compared to the bumper figures reported in 2021. Pfizer’s initial guidance for 2022 that was provided in February is targeting revenue of $98.0 billion to $102.0 billion and adjusted EPS of $6.35 to $6.55. That puts Pfizer on course to enjoy another record year for the business.

Still, Wall Street believes the outlook is too conservative even know it is coming up against record figures from last year, when both revenue and earnings almost doubled, and that it can deliver revenue of $106.8 billion and adjusted EPS of $7.10 in 2022. This suggests some expect Pfizer to upgrade its outlook at some point this year.

Pharmaceutical companies have historically been better at navigating inflationary environments and better able to pass on higher costs through to customers, but expenses will still be on the radar. Pfizer has said a rise in selling, general and administrative costs this year will be countered by a drop in R&D spending, although it is also facing a significantly higher tax rate of 16% this year compared to just 7.6% in 2021.

Where next for PFE stock?

Pfizer shares have fallen over 18% since peaking at an all-time high last December at $61.71 and today trade closer to $50.

Shares are currently testing the 200-day moving average, which currently sits at $49 and has proven to be a reliable floor for the stock since the middle of 2020. Pfizer shares have briefly fallen below this level since then but has swiftly rebounded when it has, suggesting it could temporarily sink to as low as $45 in the meantime. The RSI remains in bearish territory but trading volumes have consistently fallen over recent months and the 5-day average is almost one-third below the 100-day average.

On the upside, Pfizer shares need to recapture the 50-day sma at $51 and the 100-day sma at $53 before it can target the $55 level of resistance seen earlier this month. Beyond there, it can eye north of $56 to bring fresh all-time highs into play.

How to trade Pfizer stock

You can trade Pfizer shares with City Index in just four easy steps:

Open a City Index account, or log-in if you’re already a customer.
Search for ‘Pfizer’ in our award-winning platform
Choose your position and size, and your stop and limit levels
Place the trade

Or you can try out your trading strategy risk-free by signing up for our Demo Trading Account.

This report is intended for general circulation only. It should not be construed as a recommendation, or an offer (or solicitation of an offer) to buy or sell any financial products. The information provided does not take into account your specific investment objectives, financial situation or particular needs. Before you act on any recommendation that may be contained in this report, independent advice ought to be sought from a financial adviser regarding the suitability of the investment product, taking into account your specific investment objectives, financial situation or particular needs.

StoneX Financial Pte. Ltd., may distribute reports produced by its respective foreign entities or affiliates within the StoneX group of companies or third parties pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed to a person in Singapore who is not an accredited investor, expert investor or an institutional investor (as defined in the Securities Futures Act), StoneX Financial Pte. Ltd. accepts legal responsibility to such persons for the contents of the report only to the extent required by law. Singapore recipients should contact StoneX Financial Pte. Ltd. at 6826 9988 for matters arising from, or in connection with the report.

In the case of all other recipients of this report, to the extent permitted by applicable laws and regulations neither StoneX Financial Pte. Ltd. nor its associated companies will be responsible or liable for any loss or damage incurred arising out of, or in connection with, any use of the information contained in this report and all such liability is hereby expressly disclaimed. No representation or warranty is made, express or implied, that the content of this report is complete or accurate.

StoneX Financial Pte. Ltd. is not under any obligation to update this report.

Trading CFDs and FX on margin carries a high level of risk that may not be suitable for some investors. Consider your investment objectives, level of experience, financial resources, risk appetite and other relevant circumstances carefully. The possibility exists that you could lose some or all of your investments, including your initial deposits. If in doubt, please seek independent expert advice. Visit www.cityindex.com/en-sg/terms-and-policies for the complete Risk Disclosure Statement.

ALL TRADING INVOLVES RISKS. LOSSES CAN EXCEED DEPOSITS.

City Index is a trading name of StoneX Financial Pte. Ltd. (“SFP”) for the offering of dealing services in Contracts for Differences (“CFD”). SFP holds a Capital Markets Services Licence issued by the Monetary Authority of Singapore for Dealing in Exchange-Traded Derivatives Contracts, Over-the-Counter Derivatives Contracts, and Spot Foreign Exchange Contracts for the Purposes of Leveraged Foreign Exchange Trading. SFP is also both Derivatives Trading and Clearing member of the Singapore Exchange (“SGX”). SFP is a wholly-owned subsidiary of StoneX Group Inc.

The information provided herein is intended for general circulation. It does not take into account the specific investment objectives, financial situation or particular needs of any particular person. You should take into account your specific investment objectives, financial situation or particular needs before making a commitment to invest, including seeking advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit. No representation or warranty is given as to the accuracy or completeness of this information. Consequently, any person acting on it does so entirely at their own risk.

The information does not represent an offer of, or solicitation for, a transaction in any investment product. Any views and opinions expressed may be changed without an update. To understand the risks and costs involved, please visit the section captioned “Important Information” and the “Risk Disclosure Statement”.

The information herein is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.

StoneX Financial Pte. Ltd. 1 Raffles Place, #18-61, One Raffles Place Tower 2, Singapore 048616. Tel: 6309 1000. Co. Reg. No.: 201130598R.

This advertisement has not been reviewed by the Monetary Authority of Singapore.